Assoc. Prof. MD. Esra Turan Erkek

Education

• Associate Professor  Date of Appointment as Associate Professor: 22/03/2024
• 2011–2014 Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Haematology, Istanbul, Turkey
• 2005–2010 Dr L. Kırdar Kartal Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
• 1998–2004 Uludağ University Faculty of Medicine, Bursa, Turkey

Experience

• 2015–2026 Istanbul Dr Lütfi Kırdar City Hospital, Istanbul, Turkey
  
• 2010 Hakkari State Hospital (Internal Medicine Service Obligation)

Courses and Certificates

• XXVth Practical Flow Cytometry Training Course, Practical Flow Cytometry, Istanbul, Course, 17 June 2019 – 21 June 2019 (National)
• J&J GCO Investigator Rave Training Version 3.0, J&J GCO Investigator Rave Training, Medidata University, Course, 21 September 2012 – 21 September 2012 (International)
• Haematological Oncology and Bone Marrow Transplantation Course, Haematological Oncology and Bone Marrow Transplantation, Cyprus, Course, 7 February 2014 – 9 February 2014 (National)
• 3rd International Conference on Multiple Myeloma Course, Multiple Myeloma, Milan, Italy, Course, 7 October 2016 – 9 October 2016 (International)
• THD Flow Cytometry Training Mini-Academy 2026
• THD ITP Bite-   Class Training 2025

Master’s Thesis

Evre 1 ve Evre 2 Kronik Böbrek Yetersizliğinin Dipper ve Non Dipper Kan Basıncı Paterni Gelişimine Etkisi (2010) Tez Danışmanı Prof Dr Zerrin Bicik Bahçebaşı

Yan Dal Uzmanlık Tezi : Paroksismal Noktürnal Hemoglobinüri ve Aplastik Anemi Olgularında Doaşan Endotel Hücreleri ve Tromboza Etkisi( 2014) Tez Danışmanı ( Prof Dr Mustafa N Yenerel)

Articles published in international peer-reviewed journals (SCI, SSCI and Arts and Humanities)

1.1.1          Sahin F, Saydam G, Cömert M, Uz B, Yavuz AS, Turan E, Yönal I, Atay H, Keltikli E, Turgut M, Pehlivan M, Akay MO, Gürkan E, Paydaş S, Kahraman S, Demirkan F, Kırkızlar O, Akpınar S, Pamuk GE, Demir M, Ozbaş HM10, Sönmez M10, Gültürk M, Salihoğlu A, Eşkazan AE, Ar C, HaydaroğluŞahin H, Ongören S, Başlar Z, Aydın Y, Yenerel MN, Tüzüner N, Ferhanoğlu B, Haznedaroglu IC, Ilhan O, Soysal T.Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients.Turk J Haematol. 2013 Dec;30(4):351-8. doi: 10.4274/tjh.2013.0151. Epub 2013 Dec 5

1.1.2          TuranErkekE,Kalayoglu-BesısıkS.An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum .Turk J Haematol. 2016 Mar 5;33(1):81-2. doi: 10.4274/tjh.2015.0268

1.1.3          Turan Erkek E, Karaali CN, Yılmaz G, Gültürk E. Bleomycin-Induced Flagellate Dermatitis. Turk J Haematol. 2019 May 3;36(2):138-140. doi: 10.4274/tjh.galenos.2019.2018.0317. Epub 2019 Jan 2. PMID: 30600679; PMCID: PMC6516091.

1.1.4          Beyhan Sagmen S, Comert S, Turan Erkek E, Küçüköz Uzun A, Doğan C, Yılmaz G, Kıral N, Fidan A, Yılmaz Haksal Ç, Torun Parmaksız E. Can We Predict Bleomycin Toxicity with PET-CT? Acta Haematol. 2019;142(3):171-175. doi: 10.1159/000502374. Epub 2019 Aug 27. PMID: 31454795.

1.1.5          Dogan EE, Turan Erkek E, Elverdi T, Celik Kamaci S, Ciftci U, Demirel N, Aydin D, Eren R. Eltrombopag in the Treatment of Immune Thrombocytopenia: Two-Center Experience from Istanbul. Indian J Hematol Blood Transfus. 2022 Apr;38(2):327-332. doi: 10.1007/s12288-021-01462-5. Epub 2021 Jul 5. PMID: 35496971; PMCID: PMC9001770..

1.1.6          Erkek ET, Nazligul E, Nalcaci M, Yenerel MN. Circulating Endothelial Progenitor Cells and Their Relation to Thrombosis in Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia. Indian J Hematol Blood Transfus. 2022 Apr;38(2):319-326. doi: 10.1007/s12288-021-01445-6. Epub 2021 May 26. PMID: 35496969; PMCID: PMC9001756.

1.1.7          Uğur MC, Namdaroğlu S, Doğan EE, Turan Erkek E, Nizam N, Eren R, Bilgir O. Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura. Turk J Haematol. 2021 Aug 25;38(3):181-187. doi: 10.4274/tjh.galenos.2021.2021.0216. Epub 2021 Jun 24. PMID: 34162173; PMCID: PMC8386313.

1.1.8        Turan Erkek E, Aslan E. Additional malignancies shorten overall survival in chronic lymphocytic leukemia irrespective of chromosomal aberrations: A retrospective cohort study. Medicine (Baltimore). 2023 Feb 10;102(6):e32906. doi: 10.1097/MD.0000000000032906. PMID: 36820600; PMCID: PMC9907968.

1.1.9          Turan Erkek E, Tahtalı T. Co-occurrence of multiple thrombophilic factors with a popliteal artery embolism history: an extraordinary myelofibrosis case. Kuwait Medical Journal, September 2022 Vol 54 No:3 , 405-408

1.1.10       Erkek, ET; Isik, AC1; Ipek, Y; Kul, AN. Tyrosine Kinase Inhibitor Therapies in Chronic Myeloid Leukemia: Effects on Clinical Characteristics and Triglyceride-to-High Density Lipoprotein Cholesterol Ratio. Nigerian Journal of Clinical Practice 26(6):p 802-809, June 2023. | DOI: 10.4103/njcp.njcp_755_22

1.1.11       Tuna, MK; Erkek, ET. Is Immune Thrombocytopenia and its Treatment Associated with Sarcopenia?. Nigerian Journal of Clinical Practice 27(2):p 180-187, February 2024. | DOI: 10.4103/njcp.njcp_41_23

1.1.12       Doğan EE, Keklik Karadağ F, Aydin D, DemirelN, Sağlam S, Davulcu EA,Turan Erkek E, Eren R, Akad Soyer N; Şahin F, Saydam G. "The assessment of health-related quality of life in patients with polycythemia vera." Medicine 103.30 (2024): e38814. DOI: 10.1097/MD.0000000000038814

Articles published in other international peer-reviewed journals 

1.2.1           Ogret Y, Erkek E, OsmanbasogluE,Yonal İ, SavranOguz F, Nalcacı M, Yavuz AS, KalayogluBesısık S. Restoring of donor chimerism by thyrosine kinase inhibitor treatment in relapsed chronic myeloid leukemia after allogeneic transplantation . Tissue Antigens Volume 84, Number 1 July 2014

1.2.2           Turan Erkek E, Demir N, Ozkan G, Yavuz AS. Testicular and CutaneousRelapse in Acute Promyelocytic Leukemia Treated with All-trans Retinoic Acid and Chemotherapy. Eurasian Journal of Medicine and Oncology. Volume 1, Issue 1,2017.doi: 10.14744/ejmo.2017.87597 Pages 53-54

1.2.3           Cetinkaya Esen H, Gulturk E, Turan Erkek E, Ustaoglu M. Etiological Investigation Of Patients Visiting A Hematology Polyclinic For Anemia. EJMI. 2019; 3(3): 173-181

1.2.4           Turkmen Bekmez E, Volkan O, Demir N, Turan Erkek E, Ataman Tasan D, Aliustaoglu M. Relationship Between Rheumatoid Arthritis Activation Criteria and Serum Hepcidin Levels. EJMI. 2019; 3(4): 275-279

1.2.5           Turan Erkek E, Akın S, Ozgur Y, Aydın Z, Bicik Z. Comparison of DipperandNon-DipperHypertensionPatternsAccordingtoChronicKidneyDiseaseStage. Journal Of NephrologyAdvancesVol No:1 İssue2: 15-23 September 2019DOI: 10.14302/issn.2574-4488.jna-19-3008

1.2.6           Alp Posteki E, Turan Erkek E,Posteki G, Erkek A, Aliustaoglu M. The Correlation Between Systemic Inflammatory ResponseandSurvival in Patients with Metachronous and Synchronous Liver Metastatic Colorectal Cancer. Eurasian Journal of Medical İnvestigation.Volume:4 İssue:1-2020;4(1):17–23/ DOI:10.14744/ejmi.2019.18112

1.2.7           Doğan EE, Demirel N, Turan Erkek E, Aydın D, Mansuroğlu İ, Cömert Özkan M, Eren R. Treatment Outcomes in Hairy Cell Leukemia: Data of Patients in a Tertiary Referral Hospital in Turkey for Over 20 Years. Med J Bakirkoy 2021;17:320-326. 10.4274/BMJ.galenos.2021.85047

1.2.8           Dogan, E. E., Karadag, F. K., Aydin, D., Demirel, N., Davulcu, E. A., Erkek, E. T., ... & SAYDAM, G. (2021). The Effect of Serum Lactate Dehydrogenase (LDH) Level on the Response to Erythropoiesis Stimulating Agents in Patients with Low and Intermediate Risk Myelodysplastic Syndrome. Journal of Haematology and Stem Cell Research, 1(2), 89-97.

1.2.9           Turan Erkek E, Demir N , Erdem S, Ozkan G, Arslan O, Kalayoglu Besısık S.Erdheim–Chester disease: a single center experience. Hematology Transfusion and Cell Therapy 42:59-60.October 2020 DOI: 10.1016/j.htct.2020.09.107. LicenseCC BY-NC-ND 4.0

1.2.10        Evman, Melis Demirag, and Esra Turan Erkek. "Does Chronic Immune Thrombocytopenia Lead to Hearing Loss?." Medical Science and Discovery 9.10 (2022): 577-580.

1.2.11        Ipek Y, Erkek ET. Hematological Malignancies in the Coronavirus Disease-2019 Era: Evaluation of Patient Outcomes and the Reasons for Vaccination Hesitation. jms [Internet]. 2022Nov.24 [cited 2023Jan.9];25(4